A personalized, integrative way to think about MHT after age 60.  Just like the Three Sisters in the Blue Mountains, needs matter more than age...

Age 60 is not some kind of magical moment in time when all the rules change. But continuing hormone therapy and starting it for the first time in your 60s are actually two different decisions.  Your age is part of that conversation. It is not the whole conversation.

Many women now in their 60s went through menopause when hormone therapy was being pulled back after the first Women’s Health Initiative (WHI) reports. Some stopped despite persistent symptoms. Others were never offered much of a conversation. Now they are wondering: did I miss my chance?

The answer is more nuanced than "yes" or "no." Menopausal hormone therapy (MHT) remains our most effective treatment for hot flashes and night sweats, and it can also help protect your bone strength while it is being used. Yet the evidence becomes less certain when systemic therapy is first started after age 60 or more than about 10 years after menopause. That uncertainty deserves perspective, but not alarm.

My guiding principle: Aging is complex.  MHT is simply one tool in the toolbox for better quality of life as we get older.  Simply reducing the process to lack of estrogen or progesterone is nonsense. You are more than your hormones!

First, let’s separate two very different questions

If you are already using MHT

You do not have to stop hormone therapy simply because you turn 60 or 65. If you started near menopause, remain healthy, and are still benefiting, continuing may make sense. We still need to talk about the risks and revisit the decision as your health changes. But your birthday alone should not make that decision for you.

The conversation changes over time. A dose that was appropriate at 52 may not be ideal at 64 or 84.

How you take your hormones matters, too. We need to revisit the dose, the type, and how you are taking it—not just keep renewing the same prescription.

If you are considering starting MHT in your 60s

Starting later requires a more deliberate evaluation. We have the clearest evidence about benefits and risks in women who start before age 60 or within 10 years of menopause. We know less about starting for the first time later, especially with the combinations of transdermal estradiol and micronized progesterone commonly used today.

That does not make age 60 an automatic "no." It means I want a clear reason for treatment, a meaningful benefit for you, and a careful look at your health history.  Starting systemic MHT solely to prevent dementia, heart disease, or to extend life is not yet supported by current guidelines, although evidence for newer delivery options is accumulating. In particular, starting MHT for persistent, quality-of-life-limiting symptoms may be a different conversation for well-selected women.

What the newer research can—and cannot—tell us

Recent observational studies have produced mixed results, which is exactly why they should not be oversold.

• A large 2024 Medicare study of women using MHT beyond age 65 found more favorable associations with lower-dose therapy, non-oral routes, and estradiol rather than conjugated estrogen. Estrogen-only use was associated with lower mortality and several chronic-disease outcomes. These findings are reassuring, but they cannot prove that MHT caused those benefits. Healthier women may be more likely to receive and continue therapy, and the analysis included vaginal estrogen alongside systemic treatment.
• A 2026 health-system study reported higher cancer and cerebrovascular event rates among women who initiated therapy at 65 or older. But which hormones were these women taking and how were they taking them? Oral estrogen? A synthetic progestin? The study does not tell us.  Those details matter when we are trying to apply the findings to the treatment we are considering for an individual woman.  That limits what we can take from the study.  But the study does reinforce the need for careful consideration and individualized care for each woman considering menopause hormone therapy.
• Long-term randomized WHI follow-up showed that breast outcomes differ by regimen: conjugated estrogen alone after hysterectomy was associated with lower breast cancer incidence and mortality, while conjugated estrogen plus medroxyprogesterone increased breast cancer incidence. These results should not be generalized to every estrogen, every progestogen, every route, or every woman. Again, personalized care.
• Dementia and brain-imaging studies have not shown that starting systemic MHT later in life prevents cognitive decline. Randomized evidence in women 65 and older found increased dementia risk with combined oral conjugated estrogen and medroxyprogesterone (the synthetic progestin), while estrogen alone was neutral. Some observational studies point in different directions. For now, MHT should not be prescribed as a straight up dementia-prevention strategy.

We know MHT can help with symptoms and help prevent bone loss while you use it. What we cannot yet promise is that the hormone treatments we use today will help women live longer when started or continued through their 60s and beyond.  When you start, your health, and the type and dose of hormones all matter.

You cannot out-hormone the rest of your life

Hormones can help, but they cannot do all the work.They cannot make up for too little sleep, too little movement, smoking, too much alcohol, or a diet that is not meeting your needs. And they cannot fix an unsafe relationship or a work environment that keeps you under constant stress. In an integrative menopause plan, MHT sits beside, and not above, the other drivers of health:

• Movement: regular aerobic activity, resistance training, balance work, and enough daily movement to preserve muscle, bone, insulin sensitivity, and independence.
• Sleep: identifying hot flashes, sleep apnea, restless legs, alcohol, mood symptoms, pain, or an overactivated nervous system that may be disrupting restorative sleep.
• Nutrition: adequate protein, fiber, calcium, vitamin D and other nutrients based on individual needs; a minimally processed, plant-forward pattern; and attention to glucose, lipids, blood pressure, and body composition.
• Stress and connection: boundaries with chronically stressful people or environments, meaningful relationships, time in nature, nervous-system regulation, and professional support when needed.
• Foundational medical care: age-appropriate cancer screening, bone-density assessment, cardiovascular risk evaluation, dental and vision care, and treatment of established disease.

None of this needs to be perfect before MHT can be considered. Together, they create the foundation that allows any therapy to do its best work.

A personalized assessment before starting or continuing

A useful consultation asks more than, "How old are you?” My approach is to explore:

• What are we treating? Persistent hot flashes, night sweats, sleep disruption related to vasomotor symptoms, quality-of-life concerns, genitourinary symptoms, or bone protection each lead to a different plan.
• When did menopause occur, and when was MHT started? Chronologic age and years since menopause both matter. Continuing a therapy begun at 51 is not the same as first exposure at 64.
• What else is going on with your health? Blood pressure, lipid and glucose patterns, smoking history, migraine characteristics, liver and gallbladder health, personal and family cancer history, unexplained bleeding, clotting history, cardiovascular disease, bone density, and medications all shape the decision.
• Which type of hormone therapy makes sense for you, and how should you take it? Local vaginal estrogen may be enough for genitourinary symptoms and has a very different systemic exposure profile. When systemic treatment is appropriate, route, dose, estrogen type, and endometrial protection deserve individual consideration.
• How will we know it is helping? Agree on the symptoms or outcomes that should improve and a timeframe for reassessment. Monitoring hormone levels are an important part of personalized care.  More treatment is not automatically better treatment.

The bottom line

Your 60th birthday should not end the conversation about hormone therapy. If you started near menopause, remain healthy, and are still benefiting, continuing may make sense. We need to keep looking at the benefits and risks as your health changes. Starting for the first time in your 60s deserves a closer look, but it still deserves a conversation—not an automatic yes or no.

MHT may help you sleep, move, work, and participate more fully in your life. It can help protect bone strength while you use it. Those are meaningful benefits. But I am not going to promise that starting hormones in your 60s will prevent chronic disease or help you live longer. We do not have the evidence to make that promise.

The goal is not to be “on hormones” or “off hormones.” The goal is to build a plan that makes sense for your health and your life. 

Selected references

• Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women’s health outcomes by types, routes, and doses. Menopause. 2024;31(5):363-371. doi:10.1097/GME.0000000000002335.
• Carney A, Gluzman M, Kolushev-Ivshin I, Amar S. Health outcomes of hormone therapy initiated or continued after age 65. Menopause. 2026;33. doi:10.1097/GME.0000000000002721.
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380. doi:10.1001/jama.2020.9482.
• Pourhadi N, Mørch LS, Holm EA, Torp-Pedersen C, Meaidi A. Menopausal hormone therapy and dementia: nationwide, nested case-control study. BMJ. 2023;381:e072770. doi:10.1136/bmj-2022-072770.
• Coughlan GT, Betthauser TJ, Boyle R, Koscik RL, et al. Association of age at menopause and hormone therapy use with tau and beta-amyloid positron emission tomography. JAMA Neurology. 2023;80(5):462-473. doi:10.1001/jamaneurol.2023.0455.
• The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.